-       Report 
   - October 2025
    -  186 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Clinical Trials 
   - April 2025
    -  60 Pages 
    Global
   
   From       €1077EUR$1,200USD£945GBP 
      €1346EUR$1,500USD£1,181GBP 
                  -       Report 
   - October 2025
    -  197 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - June 2024
    -  200 Pages 
    Global
   
   From       €5707EUR$6,360USD£5,009GBP 
      €7134EUR$7,950USD£6,261GBP 
                  -       Report 
   - January 2022
    -  60 Pages 
    Global
   
   From       €2836EUR$3,160USD£2,489GBP 
      €3544EUR$3,950USD£3,111GBP 
                   -       Report 
   - May 2024
    -  129 Pages 
    Global
   
   From       €4957EUR$5,524USD£4,351GBP 
      €5832EUR$6,499USD£5,118GBP 
                -       Report 
   - February 2024
    -  87 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                      Trigeminal Neuralgia (TN) is a chronic pain disorder that affects the trigeminal nerve, one of the largest nerves in the head. It is characterized by episodes of intense, stabbing pain in the face, usually on one side. Treatment for TN typically involves medications, such as anticonvulsants, antidepressants, and muscle relaxants. These drugs are part of the Central Nervous System (CNS) drug market, which includes drugs used to treat neurological and psychiatric disorders.
The CNS drug market is    highly competitive, with many large pharmaceutical companies developing and marketing drugs for the treatment of neurological and psychiatric disorders. Companies such as Pfizer, GlaxoSmithKline, Eli Lilly, and Novartis are some of the major players in the CNS drug market. Other companies, such as Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals, also have a presence in the market. Show Less   Read more